OR WAIT null SECS
As a result, the parties will work together to advise pharma clients on subject matters pertaining to strategy and planning, market access, policy analysis, and more. .
Numerof & Associates has signed a collaborative services agreement with Koios Enterprises and Consulting. As part of that agreement, Michael L. Ryan, PharmD, Kojos’ founder, will serve as an executive advisor with the healthcare strategy firm.
More specifically, the former Bristol-Myers Squibb (BMS) and Amgen senior executive will work closely with the Numerof team to advise selected pharma clients on strategy and planning, market access, policy analysis, and evidence generation, among other services.
Ryan retired in March from BMS, where he was the SVP in charge of US and worldwide value, access, pricing, and health economics and outcomes research (HEOR) for the company’s $46 billion portfolio. Before joining BMS, he spent 16 years at Amgen, in VP and general manager roles, most recently overseeing US reimbursement, value, and access, and previously owning the P&L and US sales and marketing for nephrology.
“I’ve worked closely with Mike Ryan for more than a decade. His visionary leadership and successful track record in managing market access, pricing, and complex policy challenges across the globe is simply unparalleled,” comments Rita Numerof, PhD, president, Numerof & Associates. “We share the same passion for anticipating where global and regional markets are going, and developing the solutions needed to help companies navigate fundamental change in the face of economic and regulatory pressures. We are also committed to helping industry leaders ensure they can continue to innovate and bring new life-saving therapies to patients.”